Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma

Salivary ductal carcinomas (SDCs) are extremely rare and aggressive malignancies, accounting for approximately 6% of all salivary gland malignancies. One distinct feature is their resemblance to ductal carcinomas of breast. A significant percentage of SDCs overexpress Her2 and the use of targeted th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Muhammad Shahid Iqbal, Ghazia Shaikh, Sanjoy Chatterjee, Helen Cocks, Josef Kovarik
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	Case Reports in Oncological Medicine
Online Access:	http://dx.doi.org/10.1155/2014/162534
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
by: Zhida Wu, et al.
Published: (2025-01-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
by: Lu Wang, et al.
Published: (2025-01-01)

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2024-11-01)

The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
by: Prachi Bhatt, et al.
Published: (2024-12-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
by: Hakon Blomstrand, et al.
Published: (2020-01-01)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
by: Kirsten Merx, et al.
Published: (2016-01-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Nuclear Position and Shape Deformation of Chromosome 8 Territories in Pancreatic Ductal Adenocarcinoma
by: Sylvia Timme, et al.
Published: (2011-01-01)

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study
by: Mohamed Aseafan, et al.
Published: (2025-01-01)

Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
by: Ozden Oz, et al.
Published: (2023-07-01)

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
by: Caroline Y. K. Fong, et al.
Published: (2019-01-01)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
by: Heng‐Chung Kung, et al.
Published: (2023-04-01)

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
by: Florian Gebauer, et al.
Published: (2017-01-01)

Evaluation of Overall Survival Predictions In Inoperable Pancreas Ductal Adenocarcinoma
by: Hasan Önner, et al.
Published: (2022-02-01)

Metastatic Renal Cell Carcinoma to the Parotid Gland in the Setting of Chronic Lymphocytic Leukemia
by: Robert Deeb, et al.
Published: (2012-01-01)

Tiptoeing on Metastatic Adenocarcinoma of the Lung
by: Arupreet Kochar, et al.
Published: (2019-01-01)

Case Study of a Parotid Gland Adenocarcinoma Dedifferentiated from Epithelial-Myoepithelial Carcinoma
by: Salih Aydın, et al.
Published: (2014-01-01)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
by: Matthew Burge, et al.
Published: (2023-01-01)

Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
by: Han-Sheng Chang, et al.
Published: (2024-09-01)

A Morphological and Immunohistochemical Study of the Tumoral and Inflammatory Cells in Pancreatic Ductal Adenocarcinoma
by: Vlad Herlea, et al.
Published: (2020-01-01)

Identification of key regulators in pancreatic ductal adenocarcinoma using network theoretical approach.
by: Kankana Bhattacharjee, et al.
Published: (2025-01-01)

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
by: Nathalie B. Rasko, et al.
Published: (2025-01-01)

A versatile gold leaf immunosensor with a novel surface functionalization strategy based on protein L and trastuzumab for HER2 detection
by: Ivana Kundacina, et al.
Published: (2025-01-01)

Pilomatrixoma of the parotid region: A benign tumor mimicking metastatic cutaneous squamous cell carcinoma
by: Nikita Grieder, MD, et al.
Published: (2025-04-01)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
by: Sylvana Hidalgo, et al.
Published: (2013-01-01)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
by: Yunzhen Qian, et al.
Published: (2022-01-01)

Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells
by: Erika Stefàno, et al.
Published: (2024-01-01)

Metastatic Infiltrating Ductal Carcinoma of the Breast to the Colon: A Case Report and Literature Review
by: Salih Samo, et al.
Published: (2013-01-01)